Skip to content

Author

H. Jung

We have 3 of 28 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

A natural compound derivative targeting HADHA disrupts mitochondrial homeostasis and suppresses renal cell carcinoma.

Metastatic renal cell carcinoma (RCC) remains a lethal malignancy, and therapeutic resistance to current targeted and immune-based therapies highlights the need for new treatment strategies. Here, we identify C18-epi-brasilibactin A (CBA) as a selective inhibitor of RCC. High-throughput screening of a compound library...

Ara Jo, Sanjeevram Dhandapani, Zi-Qin Wang et al. · 0 citations
Open access Aug 2026

RUNX1T1 drives stem-like small-cell neuroendocrine prostate cancer identity

It is found that RUNX1T1 is essential for SCNPC survival, as its knockdown induced apoptotic cell death and the acquisition of PRAD-like identity, including alterations in genes involved in cell-cell adhesion and epithelial cell polarity are found.

Zi-Qin Wang, H. Jung, Changhyeon Hong et al. · 0 citations
Jul 2026

DNMT3B drives neuroendocrine lineage plasticity and aggressive progression in prostate cancer.

It is demonstrated that DNMT3B is required for both the initiation and maintenance of the NEPC phenotype, and its inhibition suppresses NEPC growth and differentiation, highlighting it as a promising therapeutic target for treatment-resistant disease.

Yunsol Jo, H. Jung, Zi-Qin Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.